Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 1733-1735, 2004; 10.1373/clinchem.2004.037895
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Levinson, S. S.
Right arrow Articles by Elin, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Levinson, S. S.
Right arrow Articles by Elin, R. J.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2004;50:1733-1735.)
© 2004 American Association for Clinical Chemistry, Inc.

Opinion

Poor Predictive Value of High-Sensitivity C-Reactive Protein Indicates Need for Reassessment

Stanley S. Levinson1,a, James J. Miller2 and Ronald J. Elin2

1 Laboratory Service, Department of Veterans Affairs Medical Center, Louisville, KY
2 Department of Pathology and Laboratory Medicine, School of Medicine, University of Louisville, Louisville, KY

aAddress correspondence to this author at: Laboratory Service, Department of Veterans Affairs Medical Center, 800 Zorn Ave., Louisville, KY 40206. Fax 502-287-6265; e-mail levinson@louisville.edu.

The first 20% of the full text of this article appears below.

Inflammation appears to be an integral part of the process of atherosclerosis that leads to coronary artery disease (CAD) and acute ischemic syndromes (1)(2). Data indicate that high-sensitivity C-reactive protein (hs-CRP) and other inflammatory markers are associated with atherosclerosis and that hs-CRP decreases with statin treatment (3)(4). These are important findings that support the inflammatory disease hypothesis. Moreover, it was suggested that hs-CRP could be used to assess risk of CAD for clinical purposes (5), and several hs-CRP assays are commercially available (6).

In this Journal, Rifai and Ridker (7) suggested an algorithm for assessing risk of CAD based on hs-CRP in conjunction with the ratio of HDL-cholesterol to total cholesterol. The algorithm was later modified to use hs-CRP cutoffs of <1, 1–3, and >3 mg/L in conjunction with the LDL-cholesterol (LDLC) concentration or the Framingham 10-year risk assessment (8). Several editorials that have accompanied reports on hs-CRP cautioned that use of this test for clinical purposes was premature (9)(10)(11)(12). In spite of these warnings, an American Heart Association/CDC Scientific Statement (13) recommended the use of this test to enhance risk evaluation in certain population groups, although they noted that the benefits of this strategy or any treatment based on it remain uncertain. The clinical recommendations of others argued for even wider use of the test, suggesting that it should be an adjunct for initial screening for global risk assessment in conjunction with conventional lipid testing (8).

We contend that because of its poor predictive value, until its use is better demonstrated, hs-CRP should not be recommended for defining risk. As . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 Annals of Clinical & Laboratory ScienceHome page
P. C. Kao, S.-C. Shiesh, and T.-J. Wu
Serum C-reactive protein as a marker for wellness assessment.
Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 163 - 169.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. B. Pepys, P. N. Hawkins, M. C. Kahan, G. A. Tennent, J. R. Gallimore, D. Graham, C. A. Sabin, A. Zychlinsky, and J. de Diego
Proinflammatory Effects of Bacterial Recombinant Human C-Reactive Protein Are Caused by Contamination With Bacterial Products, Not by C-Reactive Protein Itself
Circ. Res., November 25, 2005; 97(11): e97 - e103.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. B. Pepys
CRP or not CRP? That Is the Question
Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1091 - 1094.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Rifai
High-Sensitivity C-Reactive Protein: A Useful Marker for Cardiovascular Disease Risk Prediction and the Metabolic Syndrome
Clin. Chem., March 1, 2005; 51(3): 504 - 505.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.